Sanofi's Lunsekimig Shows Promise in Respiratory Disease Trials

French drugmaker Sanofi has shared positive results from its phase 2 clinical trials of lunsekimig, an experimental treatment aimed at chronic respiratory diseases such as asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

The company said the drug met its main and key secondary goals in two phase 2 clinical trials, showing clear improvements compared to a placebo. Lunsekimig is designed to block two key drivers of inflammation—TSLP and IL-13—both of which play a major role in airway diseases. This dual-action approach could make it more effective than existing inflammatory disease treatment options.

In the AIRCULES phase 2b trial, which involved patients with moderate-to-severe asthma, lunsekimig helped reduce asthma exacerbations and improved lung function. This is an important step forward, especially for patients who do not respond well to current therapies.

In another study, called DUET, the drug was tested in patients with CRSwNP. It successfully reduced the size of nasal polyps and eased symptoms like nasal blockage. It also showed improvement in imaging results, indicating better overall sinus health and supporting its role in nasal polyp treatment.

Also Read: AstraZeneca Brings AI Lung Cancer Screening to Telangana

However, results were mixed in a third study, VELVET, which tested the drug in people with atopic dermatitis treatment needs. While it did not meet the main goal of reducing disease severity, some improvement was seen in secondary measures, suggesting there may still be potential in this area.

Overall, lunsekimig was found to be safe and well tolerated across all studies. Most side effects were mild, including headaches, minor infections, and reactions at the injection site, reinforcing its potential as a biologic drug therapy.

Sanofi believes these results highlight the potential of lunsekimig as a new respiratory disease therapy and a promising clinical trial success in modern medicine. The drug is now moving forward into later-stage trials, but it is not yet approved for public use.

With millions of people worldwide struggling to manage asthma and related conditions, innovative treatments like lunsekimig could help address major unmet medical needs in healthcare.